Jae-Gook Shin

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5182381/publications.pdf

Version: 2024-02-01

101543 110387 4,948 149 36 64 citations g-index h-index papers 151 151 151 5779 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism. Clinical Pharmacokinetics, 2002, 41, 913-958.	3.5	771
2	Clinical Implementation of Pharmacogenomics for Personalized Precision Medicine: Barriers and Solutions. Journal of Pharmaceutical Sciences, 2017, 106, 2368-2379.	3.3	157
3	High-throughput screening of inhibitory potential of nine cytochrome P450 enzymesin vitro using liquid chromatography/tandem mass spectrometry. Rapid Communications in Mass Spectrometry, 2005, 19, 2651-2658.	1.5	148
4	Development of the "Inje Cocktail―for High-throughput Evaluation of Five Human Cytochrome P450 Isoforms in vivo. Clinical Pharmacology and Therapeutics, 2007, 82, 531-540.	4.7	121
5	Hexachlorophene Inhibits Wnt/ \hat{l}^2 -Catenin Pathway by Promoting Siah-Mediated \hat{l}^2 -Catenin Degradation. Molecular Pharmacology, 2006, 70, 960-966.	2.3	112
6	Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. British Journal of Clinical Pharmacology, 2001, 51, 277-280.	2.4	107
7	Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states*1. Clinical Pharmacology and Therapeutics, 2004, 76, 104-112.	4.7	98
8	Protein-kinase-C-mediated \hat{l}^2 -catenin phosphorylation negatively regulates the Wnt/ \hat{l}^2 -catenin pathway. Journal of Cell Science, 2006, 119, 4702-4709.	2.0	95
9	Identification and Functional Characterization of Genetic Variants of Human Organic Cation Transporters in a Korean Population. Drug Metabolism and Disposition, 2007, 35, 667-675.	3.3	93
10	Genetic polymorphisms in Na ⁺ -taurocholate co-transporting polypeptide (NTCP) and ileal apical sodium-dependent bile acid transporter (ASBT) and ethnic comparisons of functional variants of NTCP among Asian populations. Xenobiotica, 2011, 41, 501-510.	1.1	89
11	Effects of CYP2C19 and CYP2C9 genetic polymorphisms on the disposition of and blood glucose lowering response to tolbutamide in humans. Pharmacogenetics and Genomics, 2002, 12, 111-119.	5.7	86
12	Simple and accurate quantitative analysis of 20 anti-tuberculosis drugs in human plasma using liquid chromatography–electrospray ionization–tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2015, 102, 9-16.	2.8	85
13	Effect of Rifampin on the Pharmacokinetics of Rosiglitazone in Healthy Subjects. Clinical Pharmacology and Therapeutics, 2004, 75, 157-162.	4.7	82
14	LC–MS/MS for the simultaneous analysis of arachidonic acid and 32 related metabolites in human plasma: Basal plasma concentrations and aspirin-induced changes of eicosanoids. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 911, 113-121.	2.3	77
15	Characterization of Ebastine, Hydroxyebastine, and Carebastine Metabolism by Human Liver Microsomes and Expressed Cytochrome P450 Enzymes: Major Roles for CYP2J2 and CYP3A. Drug Metabolism and Disposition, 2006, 34, 1793-1797.	3.3	7 5
16	Differential effect of genetic variants of Na+-taurocholate co-transporting polypeptide (NTCP) and organic anion-transporting polypeptide 1B1 (OATP1B1) on the uptake of HMG-CoA reductase inhibitors. Xenobiotica, 2011, 41, 24-34.	1.1	74
17	Simple and accurate quantitative analysis of ten antiepileptic drugs in human plasma by liquid chromatography/tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2011, 56, 771-777.	2.8	70
18	Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19*. Clinical Pharmacology and Therapeutics, 2002, 72, 90-99.	4.7	68

#	Article	IF	CITATIONS
19	Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the genetic polymorphism. Clinical Pharmacology and Therapeutics, 2005, 78, 191-201.	4.7	68
20	Inhibitory Effects of Tricyclic Antidepressants (TCAs) on Human Cytochrome P450 Enzymes in Vitro: Mechanism of Drug Interaction between TCAs and Phenytoin. Drug Metabolism and Disposition, 2002, 30, 1102-1107.	3.3	67
21	STEREOSELECTIVE METABOLISM OF LANSOPRAZOLE BY HUMAN LIVER CYTOCHROME P450 ENZYMES. Drug Metabolism and Disposition, 2003, 31, 1227-1234.	3.3	64
22	Discovery of Novel Functional Variants and Extensive Evaluation of <i>CYP2D6 </i> Polymorphisms in Koreans. Drug Metabolism and Disposition, 2009, 37, 1464-1470.	3.3	64
23	Effect of Silymarin Supplement on the Pharmacokinetics of Rosuvastatin. Pharmaceutical Research, 2008, 25, 1807-1814.	3.5	57
24	Diclofenac attenuates Wnt/ \hat{l}^2 -catenin signaling in colon cancer cells by activation of NF- \hat{l}° B. FEBS Letters, 2005, 579, 4213-4218.	2.8	55
25	Identification and Functional Assessment of BCRP Polymorphisms in a Korean Population. Drug Metabolism and Disposition, 2007, 35, 623-632.	3.3	55
26	The Contributions of Cytochromes P450 3A4 and 3A5 to the Metabolism of the Phosphodiesterase Type 5 Inhibitors Sildenafil, Udenafil, and Vardenafil. Drug Metabolism and Disposition, 2008, 36, 986-990.	3.3	53
27	Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects. Clinical Pharmacology and Therapeutics, 2006, 79, 590-599.	4.7	52
28	The effect of ABCG2ÂV12M, Q141K and Q126X, known functional variants in vitro, on the disposition of lamivudine. British Journal of Clinical Pharmacology, 2007, 64, 645-654.	2.4	51
29	Identification and functional characterization of novel CYP2J2 variants: G312R variant causes loss of enzyme catalytic activity. Pharmacogenetics and Genomics, 2005, 15, 105-113.	1.5	50
30	Determination of acetylsalicylic acid and its major metabolite, salicylic acid, in human plasma using liquid chromatography–tandem mass spectrometry: application to pharmacokinetic study of Astrix [®] in Korean healthy volunteers. Biomedical Chromatography, 2008, 22, 590-595.	1.7	49
31	Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenetics and Genomics, 2009, 19, 103-112.	1.5	48
32	Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects. British Journal of Clinical Pharmacology, 2004, 58, 397-402.	2.4	42
33	Cytochrome P450 2B6 Catalyzes the Formation of Pharmacologically Active Sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) Metabolites in Human Liver Microsomes. Drug Metabolism and Disposition, 2008, 36, 1679-1688.	3.3	40
34	High-sensitivity liquid chromatography–tandem mass spectrometry for the simultaneous determination of five drugs and their cytochrome P450-specific probe metabolites in human plasma. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 895-896, 56-64.	2.3	39
35	CYP2C19 Poor Metabolizer Is Associated With Clinical Outcome of Clopidogrel Therapy in Acute Myocardial Infarction But Not Stable Angina. Circulation: Cardiovascular Genetics, 2013, 6, 514-521.	5.1	39
36	In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatography–Tandem Mass Spectrometry. Drug Metabolism and Disposition, 2014, 42, 1803-1810.	3.3	39

#	Article	IF	Citations
37	Comparisons of CYP2C19 Genetic Polymorphisms Between Korean and Vietnamese Populations. Therapeutic Drug Monitoring, 2007, 29, 455-459.	2.0	38
38	Identification of New <i>CYP2C19</i> Variants Exhibiting Decreased Enzyme Activity in the Metabolism of <i>S</i> -Mephenytoin and Omeprazole. Drug Metabolism and Disposition, 2009, 37, 2262-2269.	3.3	38
39	Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor. Cancer Chemotherapy and Pharmacology, 2015, 75, 173-182.	2.3	37
40	MDR1 Genetic Polymorphisms and Comparison of MDR1 Haplotype Profiles in Korean and Vietnamese Populations. Therapeutic Drug Monitoring, 2005, 27, 531-535.	2.0	36
41	Murrayafoline A attenuates the Wnt/ \hat{l}^2 -catenin pathway by promoting the degradation of intracellular \hat{l}^2 -catenin proteins. Biochemical and Biophysical Research Communications, 2010, 391, 915-920.	2.1	35
42	Stimulation of protein kinase Câ€Î± suppresses colon cancer cell proliferation by downâ€regulation of βâ€catenin. Journal of Cellular and Molecular Medicine, 2009, 13, 2171-2180.	3.6	33
43	Effect of CYP2C19 Genetic Polymorphism on Pharmacokinetics and Pharmacodynamics and Pharmacodynamics of a New Proton Pump Inhibitor, Ilaprazole. Journal of Clinical Pharmacology, 2012, 52, 976-984.	2.0	33
44	Genetic Polymorphism of CYP2C9 in a Vietnamese Kinh Population. Therapeutic Drug Monitoring, 2005, 27, 208-210.	2.0	32
45	Simultaneous determination of ebastine and its three metabolites in plasma using liquid chromatography-tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 813, 75-80.	2.3	31
46	Determination of two HMGâ€CoA reductase inhibitors, pravastatin and pitavastatin, in plasma samples using liquid chromatography–tandem mass spectrometry for pharmaceutical study. Biomedical Chromatography, 2008, 22, 131-135.	1.7	31
47	The monoterpenoids citral and geraniol are moderate inhibitors of CYP2B6 hydroxylase activity. Chemico-Biological Interactions, 2008, 174, 141-146.	4.0	31
48	Characterization of Benidipine and Its Enantiomers' Metabolism by Human Liver Cytochrome P450 Enzymes. Drug Metabolism and Disposition, 2007, 35, 1518-1524.	3.3	30
49	Identification and Characterization of Potent CYP2B6 Inhibitors in Woohwangcheongsimwon Suspension, an Herbal Preparation Used in the Treatment and Prevention of Apoplexy in Korea and China. Drug Metabolism and Disposition, 2008, 36, 1010-1015.	3.3	30
50	What Does it Take to Make Model-Informed Precision Dosing Common Practice? Report from the 1st Asian Symposium on Precision Dosing. AAPS Journal, 2019, 21, 17.	4.4	29
51	Ilaprazole, a new proton pump inhibitor, is primarily metabolized to ilaprazole sulfone by CYP3A4 and 3A5. Xenobiotica, 2012, 42, 278-284.	1.1	27
52	Role of 14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR. Cellular Signalling, 2017, 31, 124-134.	3.6	27
53	The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals. Drug Metabolism and Disposition, 2007, 35, 2095-2101.	3.3	26
54	Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3. Xenobiotica, 2015, 45, 10-18.	1.1	26

#	Article	IF	CITATIONS
55	Casein Kinase 2 (CK2)-mediated Phosphorylation of Hsp $90\hat{l}^2$ as a Novel Mechanism of Rifampin-induced MDR1 Expression. Journal of Biological Chemistry, 2015, 290, 17029-17040.	3.4	26
56	Inhibitory Interaction Potential of 22 Antituberculosis Drugs on Organic Anion and Cation Transporters of the SLC22A Family. Antimicrobial Agents and Chemotherapy, 2016, 60, 6558-6567.	3.2	26
57	Genetic polymorphism of hepatocyte nuclear factor-4α influences human cytochrome P450 2D6 activity. Hepatology, 2008, 48, 635-645.	7. 3	25
58	Contribution of GABRG2 Polymorphisms to Risk of Epilepsy and Febrile Seizure: a Multicenter Cohort Study and Meta-analysis. Molecular Neurobiology, 2016, 53, 5457-5467.	4.0	25
59	Stereoselective inhibition of cytochrome P450 forms by lansoprazole and omeprazolein vitro. Xenobiotica, 2005, 35, 27-38.	1.1	24
60	Duplex pyrosequencing assay of the 388A>G and 521T>C SLCO1B1 polymorphisms in three Asian populations. Clinica Chimica Acta, 2008, 388, 68-72.	1.1	23
61	Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index. British Journal of Clinical Pharmacology, 2013, 75, 244-253.	2.4	23
62	Pharmacogenetic Study of Deferasirox, an Iron Chelating Agent. PLoS ONE, 2013, 8, e64114.	2.5	23
63	Isoreserpine promotes \hat{l}^2 -catenin degradation via Siah-1 up-regulation in HCT116 colon cancer cells. Biochemical and Biophysical Research Communications, 2009, 387, 444-449.	2.1	22
64	Discovery of a Novel Allelic Variant of CYP2C8, CYP2C8*11, in Asian Populations and Its Clinical Effect on the Rosiglitazone Disposition In Vivo. Drug Metabolism and Disposition, 2011, 39, 711-716.	3.3	21
65	The pharmacokinetic and pharmacodynamic interaction of clopidogrel and cilostazol in relation to <i>CYP2C19</i> and <i>CYP3A5</i> genotypes. British Journal of Clinical Pharmacology, 2016, 81, 301-312.	2.4	21
66	Characterization of 22 Antituberculosis Drugs for Inhibitory Interaction Potential on Organic Anionic Transporter Polypeptide (OATP)-Mediated Uptake. Antimicrobial Agents and Chemotherapy, 2016, 60, 3096-3105.	3. 2	21
67	Determination of benidipine in human plasma using liquid chromatography–tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2004, 805, 311-314.	2.3	20
68	Identification of novel CYP4F2 genetic variants exhibiting decreased catalytic activity in the conversion of arachidonic acid to 20-hydroxyeicosatetraenoic acid (20-HETE). Prostaglandins Leukotrienes and Essential Fatty Acids, 2018, 131, 6-13.	2.2	20
69	Analysis of benidipine enantiomers in human plasma by liquid chromatography–mass spectrometry using a macrocyclic antibiotic (Vancomycin) chiral stationary phase column. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 814, 75-81.	2.3	19
70	Duplex pyrosequencing of the TPMTâŽ3C and TPMTâŽ6 alleles in Korean and Vietnamese populations. Clinica Chimica Acta, 2008, 398, 82-85.	1.1	19
71	Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. Journal of Human Genetics, 2010, 55, 189-193.	2.3	19
72	Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB. Yonsei Medical Journal, 2015, 56, 961.	2.2	19

#	Article	IF	CITATIONS
73	Analysis of genetic polymorphism and biochemical characterization of a functionally decreased variant in prostacyclin synthase gene (CYP8A1) in humans. Archives of Biochemistry and Biophysics, 2015, 569, 10-18.	3.0	19
74	Comprehensive Substrate Characterization of 22 Antituberculosis Drugs for Multiple Solute Carrier (SLC) Uptake Transporters <i>In Vitro</i> . Antimicrobial Agents and Chemotherapy, 2018, 62, .	3.2	19
75	Potential of pranlukast and zafirlukast in the inhibition of human liver cytochrome P450 enzymes. Xenobiotica, 2004, 34, 429-438.	1.1	18
76	A haplotype of <i>CYP2C9</i> associated with warfarin sensitivity in mechanical heart valve replacement patients. British Journal of Clinical Pharmacology, 2010, 70, 213-221.	2.4	18
77	Robust CYP2D6 genotype assay including copy number variation using multiplex single-base extension for Asian populations. Clinica Chimica Acta, 2010, 411, 2043-2048.	1.1	18
78	Evaluation of <i>para</i> -Aminosalicylic Acid as a Substrate of Multiple Solute Carrier Uptake Transporters and Possible Drug Interactions with Nonsteroidal Anti-inflammatory Drugs <i>In Vitro</i> Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	18
79	The effect of <i>Ginkgo biloba</i> extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy <scp>K</scp> orean subjects. British Journal of Clinical Pharmacology, 2014, 77, 821-830.	2.4	17
80	Cost Effectiveness of Genotype-Guided Warfarin Dosing in Patients with Mechanical Heart Valve Replacement Under the Fee-for-Service System. Applied Health Economics and Health Policy, 2017, 15, 657-667.	2.1	17
81	Increased serum bile acid concentration following low-dose chronic administration of thioacetamide in rats, as evidenced by metabolomic analysis. Toxicology and Applied Pharmacology, 2015, 288, 213-222.	2.8	16
82	Absolute bioavailability and pharmacokinetics of the angiotensin II receptor antagonist fimasartan in healthy subjects. Journal of Clinical Pharmacology, 2016, 56, 576-580.	2.0	16
83	Expression of CYP4V2 in human THP1 macrophages and its transcriptional regulation by peroxisome proliferator-activated receptor gamma. Toxicology and Applied Pharmacology, 2017, 330, 100-106.	2.8	16
84	Genetic Variations in UDP-glucuronosyltransferase 2B7 Gene (UGT2B7) in a Korean Population. Drug Metabolism and Pharmacokinetics, 2010, 25, 398-402.	2.2	15
85	The disposition of three phosphodiesterase type 5 inhibitors, vardenafil, sildenafil, and udenafil, is differently influenced by the CYP3A5 genotype. Pharmacogenetics and Genomics, 2011, 21, 820-828.	1.5	15
86	Multiple Cytochrome P450 Isoforms Are Involved in the Generation of a Pharmacologically Active Thiol Metabolite, whereas Paraoxonase 1 and Carboxylesterase 1 Catalyze the Formation of a Thiol Metabolite Isomer from Ticlopidine. Drug Metabolism and Disposition, 2014, 42, 141-152.	3.3	15
87	NAT2 slow acetylator is associated with anti-tuberculosis drug-induced liver injury severity in indonesian population. Pharmacogenomics, 2019, 20, 1303-1311.	1.3	15
88	Chlorpropamide 2-hydroxylation is catalysed by CYP2C9 and CYP2C19 in vitro: chlorpropamide disposition is influenced by CYP2C9, but not by CYP2C19 genetic polymorphism. British Journal of Clinical Pharmacology, 2005, 59, 552-563.	2.4	14
89	Pomegranate juice does not affect the disposition of simvastatin in healthy subjects. European Journal of Drug Metabolism and Pharmacokinetics, 2016, 41, 339-344.	1.6	14
90	Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers. Drug Metabolism and Pharmacokinetics, 2016, 31, 107-116.	2.2	14

#	Article	IF	CITATIONS
91	A Randomized, Double-Blind Trial Comparing the Pharmacokinetics of CT-P16, a Candidate Bevacizumab Biosimilar, with its Reference Product in Healthy Adult Males. BioDrugs, 2019, 33, 173-181.	4.6	14
92	Isoniazid Population Pharmacokinetics and Dose Recommendation for Korean Patients With Tuberculosis Based on Target Attainment Analysis. Journal of Clinical Pharmacology, 2021, 61, 1567-1578.	2.0	14
93	Survey of physicians' views on the clinical implementation of pharmacogenomics-based personalized therapy. Translational and Clinical Pharmacology, 2020, 28, 34.	0.9	14
94	Simultaneous determination of udenafil and its active metabolite, DAâ€8164, in human plasma and urine using ultraâ€performance liquid chromatography–tandem mass spectrometry: application to a pharmacokinetic study. Biomedical Chromatography, 2008, 22, 939-946.	1.7	13
95	Itraconazole and Rifampin Alter Significantly the Disposition and Antihistamine Effect of Ebastine and Its Metabolites in Healthy Participants. Journal of Clinical Pharmacology, 2010, 50, 195-204.	2.0	13
96	Simple and Sensitive Assay of Torasemide in Human Plasma by High-Performance Liquid Chromatography Using a Monolithic Silica Column. Chromatographia, 2004, 60, 639-643.	1.3	12
97	Characterization of urinary metabolites as biomarkers of colistin-induced nephrotoxicity in rats by a liquid chromatography/mass spectrometry-based metabolomics approach. Toxicology Letters, 2016, 248, 52-60.	0.8	12
98	Functional characterization of a common CYP4F11 genetic variant and identification of functionally defective CYP4F11 variants in erythromycin metabolism and 20-HETE synthesis. Archives of Biochemistry and Biophysics, 2017, 620, 43-51.	3.0	12
99	Development of population pharmacokinetics model of isoniazid in Indonesian patients with tuberculosis. International Journal of Infectious Diseases, 2022, 117, 8-14.	3.3	12
100	Identification of a null allele of cytochrome P450 3A7: CYP3A7 polymorphism in a Korean population. Molecular Biology Reports, 2010, 37, 213-217.	2.3	11
101	Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4â€hydroxybupropion, in healthy subjects. British Journal of Clinical Pharmacology, 2010, 70, 126-131.	2.4	11
102	Resolution of a clinical AmpliChip CYP450 Testâ, ¢ no call: discovery and characterization of novel <i>CYP2D6*1</i> haplotypes. Pharmacogenomics, 2014, 15, 1175-1184.	1.3	11
103	Characterization of the cytochrome P450 enzymes involved in the metabolism of a new cardioprotective agent KR-33028. Toxicology Letters, 2006, 166, 105-114.	0.8	10
104	The Tyrosine Kinase Inhibitor Nilotinib Selectively Inhibits CYP2C8 Activities in Human Liver Microsomes. Drug Metabolism and Pharmacokinetics, 2013, 28, 462-467.	2.2	10
105	Pharmacokinetics and Pharmacodynamics of Tegoprazan Coadministered With Amoxicillin and Clarithromycin in Healthy Subjects. Journal of Clinical Pharmacology, 2021, 61, 913-922.	2.0	10
106	A 10-gene biosignature of tuberculosis treatment monitoring and treatment outcome prediction. Tuberculosis, 2021, 131, 102138.	1.9	10
107	The effect of CYP2C19 genotype on the time course of platelet aggregation inhibition after clopidogrel administration. Journal of Clinical Pharmacology, 2014, 54, 850-857.	2.0	9
108	Genetic polymorphisms of CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in Vietnamese-Koreans. Translational and Clinical Pharmacology, 2014, 22, 70.	0.9	8

#	Article	IF	Citations
109	Population Pharmacokinetic–Pharmacodynamic Analysis to Compare the Effect of Moxifloxacin on QT Interval Prolongation Between Healthy Korean and Japanese Subjects. Clinical Therapeutics, 2016, 38, 2610-2621.	2.5	8
110	Influences of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. Drug Metabolism and Pharmacokinetics, 2019, 34, 201-208.	2.2	8
111	Semi-Automated Therapeutic Drug Monitoring as a Pillar toward Personalized Medicine for Tuberculosis Management. Pharmaceutics, 2022, 14, 990.	4.5	8
112	In vitro metabolism of a new cardioprotective agent, KR-32570, in human liver microsomes. Rapid Communications in Mass Spectrometry, 2006, 20, 837-843.	1.5	7
113	<i>In vitro</i> metabolism and transport of the new dipeptidyl peptidase 4 inhibitors, KR66222 and KR66223. Xenobiotica, 2011, 41, 445-455.	1.1	7
114	Comparative pharmacokinetics of a fixed-dose combination vs concomitant administration of telmisartan and S-amlodipine in healthy adult volunteers. Drug Design, Development and Therapy, 2017, Volume 11, 3543-3550.	4.3	7
115	Physiologically Based Pharmacokinetic Modeling Approach to Predict Drugâ€Drug Interactions With Ethionamide Involving Impact of Genetic Polymorphism on FMO3. Journal of Clinical Pharmacology, 2019, 59, 880-889.	2.0	7
116	In vitro metabolism of a new cardioprotective agent, KR-33028 in the human liver microsomes and cryopreserved human hepatocytes. Archives of Pharmacal Research, 2005, 28, 1287-1292.	6.3	6
117	Effect of HNF4α genetic polymorphism G60D on the pharmacokinetics of CYP2D6 substrate tolterodine in healthy Korean individuals. Pharmacogenetics and Genomics, 2013, 23, 175-179.	1.5	6
118	Development of a Physiologically Based Pharmacokinetic Model of Ethionamide in the Pediatric Population by Integrating Flavinâ€Containing Monooxygenase 3 Maturational Changes Over Time. Journal of Clinical Pharmacology, 2018, 58, 1347-1360.	2.0	6
119	Effects of clopidogrel and clarithromycin on the disposition of sibutramine and its active metabolites M1 and M2 in relation to CYP2B6*6 polymorphism. Xenobiotica, 2013, 43, 211-218.	1.1	5
120	Development of a Multiplex and Cost-Effective Genotype Test toward More Personalized Medicine for the Antiplatelet Drug Clopidogrel. International Journal of Molecular Sciences, 2014, 15, 7699-7710.	4.1	5
121	Antiepileptic drug-induced severe cutaneous adverse reactions and <i>HLA</i> alleles: A report of five cases with lymphocyte activation test. Translational and Clinical Pharmacology, 2019, 27, 64.	0.9	5
122	Pharmacokinetics of Single Doses of BI 425809 in Healthy Chinese and Japanese Subjects: A Randomized Study. Clinical Therapeutics, 2019, 41, 961-971.	2.5	5
123	Effect of Cilostazol on the Pharmacokinetics of Simvastatin in Healthy Subjects. BioMed Research International, 2019, 2019, 1-6.	1.9	5
124	Single Nucleotide Polymorphisms in SULT1A1 and SULT1A2 in a Korean Population. Drug Metabolism and Pharmacokinetics, 2013, 28, 372-377.	2.2	4
125	EnantioselectiveN-Demethylation and Hydroxylation of Sibutramine in Human Liver Microsomes and Recombinant Cytochrome P-450 Isoforms. Journal of Toxicology and Environmental Health - Part A: Current Issues, 2014, 77, 1419-1430.	2.3	4
126	Rifampin Induces Expression of P-glycoprotein on the THP1 Cell–Derived Macrophages, Causing Decrease Intramacrophage Concentration of Prothionamide. Journal of Pharmaceutical Sciences, 2019, 108, 3106-3111.	3.3	4

#	Article	IF	Citations
127	Identification and functional characterization of CYP4V2 genetic variants exhibiting decreased activity of lauric acid metabolism. Annals of Human Genetics, 2020, 84, 400-411.	0.8	4
128	Inhibition of 20-hydroxyeicosatetraenoic acid (20-HETE) glucuronidation by non-steroidal anti-inflammatory drugs in human liver microsomes and recombinant UDP-glucuronosyltransferase enzymes. Prostaglandins Leukotrienes and Essential Fatty Acids, 2020, 153, 102055.	2.2	4
129	Effect of rifampin on enantioselective disposition and antiâ€hypertensive effect of benidipine. British Journal of Clinical Pharmacology, 2019, 85, 737-745.	2.4	3
130	Identification and functional study of genetic polymorphisms in cyclic nucleotide phosphodiesterase 3A (PDE3A). Annals of Human Genetics, 2021, 85, 80-91.	0.8	3
131	Paraâ€nminosalicylic acid significantly reduced tenofovir exposure in human subjects; mismatched findings from in vitro to in vivo translational research. British Journal of Clinical Pharmacology, 2021, , .	2.4	3
132	Physiologically-based pharmacokinetic modeling of nafamostat to support dose selection for treatment of pediatric patients with COVID-19. Translational and Clinical Pharmacology, 2022, 30, 24.	0.9	3
133	Enzyme kinetic study of a new cardioprotective agent, KR-32570 using human liver microsomes and recombinant CYP isoforms. Archives of Pharmacal Research, 2007, 30, 469-474.	6.3	2
134	The virological response in Koreans infected with HCV genotype 1 did not differ between groups treated with a full dose or reduced dose (≥80Â% full dose) of peginterferon alfa-2a: a prospective randomized multicenter trial. Hepatology International, 2013, 7, 1000-1009.	4.2	2
135	The frequency of the known mitochondrial variants associated with drug-induced toxicity in a Korean population. BMC Medical Genomics, 2022, 15, 3.	1.5	2
136	Characterization of Clofazimine as a Potential Substrate of Drug Transporter. Antimicrobial Agents and Chemotherapy, 2022, 66, e0215821.	3.2	2
137	Center for Personalized Precision Medicine for Tuberculosis: Smart Research and Development Workstation. Healthcare Informatics Research, 2022, 28, 176-180.	1.9	2
138	Rapid genotyping of the genetic variants of organic anion transporter 1 (OAT1), R50H, R23W, R454Q, and 505C>T, by pyrosequencing method. Journal of Pharmaceutical Investigation, 2012, 42, 71-76.	5.3	1
139	Genetic Variations in UDP-glucuronosyltransferase 2B15 in a Korean Population. Drug Metabolism and Pharmacokinetics, 2014, 29, 105-109.	2.2	1
140	The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. Journal of Clinical Pharmacology, 2016, 56, 1372-1377.	2.0	1
141	Associations between HLA-A, -B, and -C alleles and iodinated contrast media–induced hypersensitivity in Koreans. Translational and Clinical Pharmacology, 2021, 29, 107.	0.9	1
142	The Pharmacogenomics of Cytochrome P450s: From Molecular to Clinical Application., 2014,, 345-370.		1
143	Reply to: Letter to the Editor "Impact of the CYP2C19*17 Polymorphism on the Pharmacokinetics and Pharmacodynamics of Proton Pump Inhibitorsâ€, Journal of Clinical Pharmacology, 2013, 53, 360-360.	2.0	0
144	Ongoing Initiatives in Bringing the Preemptive Panelâ€"Based Pharmacogenetic Testing to Clinical Decisions in Vietnam. IFMBE Proceedings, 2022, , 553-567.	0.3	0

#	Article	IF	CITATIONS
145	The Development of Automated Bed-allocation Expert System in Clinical Research Ward. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 2012, 20, 51.	0.1	0
146	Bioequivalence of Generic Nortriptyline Tablet. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, $1993,1,3.$	0.1	0
147	Assessment of Efficacy and Safety of Haloxazolam in Psychiatric Patients with Insomnia. Journal of the Korean Society for Clinical Pharmacology and Therapeutics, 1995, 3, 36.	0.1	0
148	THE EFFECTS OF CANDIDATE GENE IN PKPD PATHWAY ON ANTIPSYCHOTICS-INDUCED AMENORRHEA IN FEMALE SCHIZOPHRENIA PATIENTS. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO4-10-24.	0.0	0
149	Effects of cytochrome b5 expression and its genetic variant on the activity of CYP2C9, CYP2C19 and CYP3A4. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO3-14-15.	0.0	0